APPLICATION FOR SUBSIDY **BY SPECIAL AUTHORITY**

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:

Olaparib

Initial application — Ovarian cancer

Applications only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)

and and	There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation					
		Patient has newly diagnosed, advanced disease				
		Patient has received one line** of previous treatment with platinum-based chemotherapy				
		Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen				
	or					
		Patient has received at least two lines** of previous treatment with platinum-based chemotherapy and				
		Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy				
		And Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen				
		Patient has not previously received funded olaparib treatment				
and						
	Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen					
and	d Treatment to be administered as maintenance treatment					
and						

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries	to Ministry	of Health
0800 855	066	

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:

Olaparib - continued

Renewal — Ovarian cancer					
Current approval Number (if known):					
Applications only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months. Prerequisites (tick boxes where appropriate)					
Treatment remains clinically appropriate and patient is benefitting from treatment					
No evidence of progressive disease					
Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion					
and Treatment to be administered as maintenance treatment and					
and					
Patient has received one line** of previous treatment with platinum-based chemotherapy and					
Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years					
or Patient has received at least two lines** of previous treatment with platinum-based chemotherapy					

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component. **A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

I confirm the above details are correct and that in signing this form I understand I may be audited.